We are live on ! Find out more
NAGE

Niagen Bioscience

50 hedge funds and large institutions have $12.8M invested in Niagen Bioscience in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

4% more funds holding

Funds holding: 4850 (+2)

22% less capital invested

Capital invested by funds: $16.5M → $12.8M (-$3.7M)

Holders
50
Holders Change
+2
Holders Change %
+4.17%
% of All Funds
1.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
16
Reduced
13
Closed
4
Calls
$144K
Puts
Net Calls
+$144K
Net Calls Change
-$75K
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
51
Coe Capital Management
Illinois
-$683K -164,994 Closed
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
-$45.6K -12,427 Closed
TRCT
53
Tower Research Capital (TRC)
New York
-$5K -1,089 Closed
Simplex Trading
54
Simplex Trading
Illinois
-$1K -252 Closed

NAGE Hedge Fund Activity: Q3 2016 in Review

50 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2016, worth a combined $12.8M — down 22% from $16.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NAGE positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was North Star Investment Management, opening a new position worth an estimated $997K. The largest seller was Coe Capital Management, exiting entirely with an estimated $683K sold.

  • 50 institutional investors held Niagen Bioscience (NAGE) as of Q3 2016, up from 48 in Q2 2016.
  • Funds reported $12.8M of Niagen Bioscience stock for Q3 2016, down 22% quarter-over-quarter.
  • 6 funds opened new Niagen Bioscience positions in Q3 2016 and 4 closed out, a net change of +2 holders.
  • The largest Niagen Bioscience buyer in Q3 2016 was North Star Investment Management, an estimated $997K added.
  • The largest Niagen Bioscience seller in Q3 2016 was Coe Capital Management, an estimated $683K sold.

Based on aggregated 13F filings for Q3 2016.